BMY vs VRTX: stock comparison and AI forecast
Bristol Myers Squibb Co (BMY) and Vertex Pharmaceuticals Inc / Ma (VRTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMY Bristol Myers Squibb Co
- Market Cap
- $129.04B
- P/E Ratio
- 14.0x
- Size
- large-cap
- AI Forecast
VRTX Vertex Pharmaceuticals Inc / Ma
- Market Cap
- $137.50B
- P/E Ratio
- 34.9x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BMY and VRTX have similar market capitalizations ($129.04B and $137.50B).
- BMY trades at 14.0 times trailing earnings, VRTX at 34.9 times.
- VRTX turns 30.7% of its revenue into net income, against 18.5% for BMY.
- BMY carries 2.79 times debt per unit of equity, against 0.57 times for VRTX.
- BMY yields 3.97% in dividends; VRTX pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMY | VRTX |
|---|---|---|
| Market Cap | $129.04B | $137.50B |
| P/E Ratio | 13.97x | 34.93x |
| P/B Ratio | 5.51x | 6.58x |
| Dividend Yield | 3.97% | – |
| EPS | $4.52 | $15.53 |
| Book Value/Share | $11.45 | $82.49 |
| Revenue/Share | $24.48 | $51.10 |
| FCF/Share | $4.54 | $12.63 |
Profitability & Margins
| Metric | BMY | VRTX |
|---|---|---|
| ROE | 39.5% | 19.0% |
| ROA | 10.4% | 12.2% |
| ROIC | – | 15.5% |
| Gross Margin | 69.2% | 85.5% |
| Operating Margin | – | 33.2% |
| Net Margin | 18.5% | 30.7% |
| EBT Margin | 22.6% | 36.8% |
| Tax Rate | 18.4% | 16.5% |
Financial Health
| Metric | BMY | VRTX |
|---|---|---|
| Current Ratio | 1.59x | 2.34x |
| Quick Ratio | 1.44x | 1.89x |
| D/E Ratio | 2.79x | 0.57x |
| Financial Leverage | 3.79x | 1.57x |
| Interest Coverage | 42.5x | 245.8x |
| Working Capital | $11.01B | $6.69B |
Cash Flow
| Metric | BMY | VRTX |
|---|---|---|
| Operating Cash Flow | $10.65B | $3.69B |
| Free Cash Flow | $9.29B | $3.20B |
| Capital Spending | -$1.37B | -$492M |
| OCF Growth YoY | -35.9% | -0.6% |
| FCF Growth YoY | -39.3% | -4.0% |
| FCF/Sales | 18.6% | 24.7% |
| CapEx/Sales | 2.7% | 3.8% |
Operational Efficiency
| Metric | BMY | VRTX |
|---|---|---|
| Asset Turnover | 0.56x | 0.40x |
| Receivables Turnover | 5.4x | 5.6x |
| Inventory Turnover | 5.7x | 0.8x |
| Fixed Assets Turnover | 6.3x | 7.6x |
| Days Sales Outstanding | 67 days | 65 days |
| Days Inventory | 64 days | 437 days |
| Payables Period | 110 days | 92 days |
| Cash Conversion Cycle | 21 days | 410 days |
Income Statement
| Metric | BMY | VRTX |
|---|---|---|
| Total Revenue | $50.03B | $12.95B |
| Operating Income | – | $4.30B |
| Net Income | $9.24B | $3.98B |
| R&D Expense | $10.56B | $4.25B |
| SG&A Expense | $7.32B | $2.41B |
| Cost of Goods Sold | $15.39B | $1.87B |
Dividend & Shareholder Information
| Metric | BMY | VRTX |
|---|---|---|
| Dividends Per Share | $2.50 | – |
| Payout Ratio | 55.3% | – |
| Shares Outstanding | 2044M | 253M |
| Net Income Growth | 53.1% | 8.2% |
| EPS Growth | 52.2% | 8.6% |
BMY vs VRTX: stock comparison and AI forecast
Which is bigger, BMY or VRTX?
BMY and VRTX have similar market capitalizations ($129.04B and $137.50B).
Which is cheaper on earnings, BMY or VRTX?
BMY trades at 14.0 times trailing earnings, VRTX at 34.9 times.
Which one does Intratio's AI model rank higher, BMY or VRTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.